Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal(TM), an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonstrates non-inferiority in all the endpoints of the study, compared to Androgel(R), a cream which is the leading treatment for low testosterone. read more: http://www.bio-medicine.org/medicine...onadism-451-1/
Androxal Shows Highly Statistically Significant Positive,Effects in Men with
Collapse
X
Comment